AMBER BOUTWELL: Open Payments
NPI 1891299541 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$785 in 34 payments from 6 companies in 2025. Trend: 2023 $442 · 2024 $641 · 2025 $785
Food & beverage: $785
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 14 | $350 |
| Neurocrine BioSciences, Inc. | 6 | $137 |
| Otsuka America Pharmaceutical, Inc. | 6 | $114 |
| E.R. Squibb & Sons, L.L.C. | 6 | $114 |
| Janssen Pharmaceuticals, Inc | 1 | $40 |
| Teva Pharmaceuticals USA, Inc. | 1 | $29 |
Products named: ARISTADA, INGREZZA, COBENFY, ABILIFY ASIMTUFII, INVEGA SUSTENNA, UZEDY, ABILIFY MAINTENA.
Industry payments across LA — which companies pay providers there.
